Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

NCT02118064 is registered in ClinicalTrials.gov with Cancer Advances Inc. as lead sponsor.

NCT NCT02118064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02118064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.
Lead sponsor
Cancer Advances Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2001
Completion date
Not reported
Enrollment
161 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer